Plasma cell dyscrasias (PCDs) are a group of diseases, including Multiple Myeloma, characterized by the presence of monoclonal proteins in the blood or urine due to plasma cell proliferation in the bone marrow. The presenting symptoms can often mimic those of more common conditions, such as diabetes. To accurately screen for and diagnose these disorders, various tests are required, including but not limited to serum protein electrophoresis (SPEP), serum and urine immunofixation (IFE), and serum free light chain assays.
Abstract
Dr. Joseph Mikhael will discuss healthcare disparities that contribute to delayed Multiple Myeloma diagnoses and poor outcomes, emphasizing the need for targeted screening in high-risk Black/African American and Hispanic communities with comorbidities.
Dr. Christopher Farnsworth will present a comparative study of two serum free light chain assays—Freelite and Sebia ELISA—conducted on 176 patients with comorbidities, excluding Multiple Myeloma and other plasma cell disorders, 33% of whom are Black/African American. This webinar will examine the clinical specificity of these assays (68.7% vs. 87.5%) in diagnosing plasma cell disorders in patients with complex health conditions.
Learning Objectives
このセクションには、広く配布されることを意図した情報が含まれているため、あなたの国では利用できない、または有効でない製品の詳細や情報が含まれている場合があります。
SEBIA JAPAN 株式会社にお問い合わせください。医療従事者を対象とした情報を提供しています。
試薬の添付文書や機器のマニュアルに記載されている内容を注意深く読んでください。